{"id":"NCT04484857","sponsor":"FibroGen","briefTitle":"Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants","officialTitle":"Phase 3b Multicenter, Open-Label Single Arm Study of Roxadustat: Either as Conversion From an Erythropoiesis Stimulating Agent (ESA), or as Initial Anemia Treatment in Hemodialysis (HD) Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-07-22","primaryCompletion":"2021-07-09","completion":"2021-09-17","firstPosted":"2020-07-24","resultsPosted":"2022-07-26","lastUpdate":"2022-07-26"},"enrollment":283,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia Associated With End Stage Renal Disease"],"interventions":[{"type":"DRUG","name":"Roxadustat","otherNames":[]}],"arms":[{"label":"Roxadustat","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the safety and effectiveness of roxadustat dosing regimens among hemodialysis participants converted from erythropoiesis stimulating agent (ESA) therapy or who are ESA-naïve.","primaryOutcome":{"measure":"Percentage of Participants With Mean Hb Value ≥10 g/dL","timeFrame":"Week 16 through Week 24","effectByArm":[{"arm":"Roxadustat","deltaMin":83.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":26,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":82,"n":283},"commonTop":["COVID-19"]}}